US FDA approves Takeda, Protagonist's drug for rare blood cancer
来源：Reuters发布于 2026-08-28
The U.S. Food and Drug Administration has approved a first-of-its-kind drug from Takeda Pharmaceutical and Protagonist Therapeutics to treat a rare blood cancer, the health regulator said o...
相关标的：TAK
本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。